Mesoblast Limited reported net sales of $30.3 million for its flagship product, Ryoncil (remestemcel‑L), in the quarter ended March 31 2026, bringing cumulative first‑year revenue to nearly $100 million.
The quarter’s sales were up 1 % from the $30.0 million net revenue reported for the fourth quarter of FY25 and more than double the $19.1 million net sales recorded in the third quarter of FY25, underscoring a clear acceleration in commercial uptake as the company moves beyond the initial launch phase.
Strong demand in February and March offset the typical January slowdown, with the company citing robust uptake in both pediatric and adult indications as the primary drivers of the year‑to‑date momentum.
Dr. Silviu Itescu, Mesoblast’s chief executive, said, "Revenue for Ryoncil continues to be impressive. We will outline our growth strategy for Ryoncil as well as our robust late‑stage product pipeline at our inaugural R&D event this week." The R&D Day is scheduled for April 8 2026.
The results reinforce Mesoblast’s commercial traction and strengthen its balance sheet, providing a foundation for future product launches and pipeline development. Ryoncil’s status as the first FDA‑approved mesenchymal stromal cell therapy and its high gross margin of 93 % give the company a unique competitive position in the cell‑based therapeutics market.
While the company faces ongoing profitability challenges—operating and net margins have hovered near 0 % in some analyses—the strong demand for Ryoncil and the company’s strategic focus on expanding indications and advancing its broader pipeline signal a resilient outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.